RU2420519C2 - Пиримидинамидные соединения как ингибиторы pgds - Google Patents

Пиримидинамидные соединения как ингибиторы pgds Download PDF

Info

Publication number
RU2420519C2
RU2420519C2 RU2008117170/04A RU2008117170A RU2420519C2 RU 2420519 C2 RU2420519 C2 RU 2420519C2 RU 2008117170/04 A RU2008117170/04 A RU 2008117170/04A RU 2008117170 A RU2008117170 A RU 2008117170A RU 2420519 C2 RU2420519 C2 RU 2420519C2
Authority
RU
Russia
Prior art keywords
carboxylic acid
pyrimidine
fluorophenyl
phenylpyrimidine
amide
Prior art date
Application number
RU2008117170/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2008117170A (ru
Inventor
Сьюзан С. ОЛДОУС (US)
Сьюзан С. ОЛДОУС
Джон Цзыци ЦЗЯНЬ (US)
Джон Цзыци ЦЗЯНЬ
Цзиньци ЛУ (US)
Цзиньци Лу
Лян МА (US)
Лян МА
Лань МУ (US)
Лань МУ
Хэрри Рендалл МАНСОН (US)
Хэрри Рендалл МАНСОН
Джеффри Стефен СЕЙБОЛ (US)
Джеффри Стефен Сейбол
Сукантхини ТХУРАЙРАТНАМ (US)
Сукантхини Тхурайратнам
Кристофер Лорен ВАНДЮЗЕН (US)
Кристофер Лорен Вандюзен
Original Assignee
Авентис Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авентис Фармасьютикалз Инк. filed Critical Авентис Фармасьютикалз Инк.
Publication of RU2008117170A publication Critical patent/RU2008117170A/ru
Application granted granted Critical
Publication of RU2420519C2 publication Critical patent/RU2420519C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2008117170/04A 2005-10-04 2006-10-04 Пиримидинамидные соединения как ингибиторы pgds RU2420519C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72357005P 2005-10-04 2005-10-04
US60/723,570 2005-10-04

Publications (2)

Publication Number Publication Date
RU2008117170A RU2008117170A (ru) 2009-11-10
RU2420519C2 true RU2420519C2 (ru) 2011-06-10

Family

ID=37635758

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008117170/04A RU2420519C2 (ru) 2005-10-04 2006-10-04 Пиримидинамидные соединения как ингибиторы pgds

Country Status (27)

Country Link
US (1) US8202863B2 (https=)
EP (1) EP1937652B1 (https=)
JP (1) JP5452925B2 (https=)
KR (1) KR101457966B1 (https=)
CN (2) CN101538246B (https=)
AR (1) AR056871A1 (https=)
AU (1) AU2006299428B2 (https=)
BR (1) BRPI0616815A2 (https=)
CA (1) CA2624749C (https=)
CR (1) CR9832A (https=)
DO (1) DOP2006000210A (https=)
EC (1) ECSP088335A (https=)
ES (1) ES2514471T3 (https=)
IL (1) IL190411A (https=)
MA (1) MA29925B1 (https=)
MY (1) MY151172A (https=)
NO (1) NO20082000L (https=)
NZ (1) NZ567208A (https=)
PE (2) PE20110118A1 (https=)
RU (1) RU2420519C2 (https=)
SG (1) SG166121A1 (https=)
TN (1) TNSN08104A1 (https=)
TW (1) TWI415839B (https=)
UA (1) UA93213C2 (https=)
UY (1) UY29840A1 (https=)
WO (1) WO2007041634A1 (https=)
ZA (1) ZA200802222B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2655914C2 (ru) * 2012-08-24 2018-05-30 Саншайн Лейк Фарма Ко., Лтд. Соединения дигидропиримидина и их применение в фармацевтических препаратах

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759350B2 (en) * 2005-09-15 2010-07-20 Orchid Research Laboratories Ltd. Pyrimidine carboxamides
PE20110118A1 (es) 2005-10-04 2011-03-08 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
CA2648202A1 (en) 2006-04-11 2007-10-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
EP2129660A2 (en) 2006-12-19 2009-12-09 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
JP2010519328A (ja) 2007-02-26 2010-06-03 ファイザー・プロダクツ・インク H−pgdsの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンd2が媒介する疾患の治療のためのそれらの使用
AU2008293542B9 (en) 2007-08-27 2014-08-07 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
AU2008310661A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
CA2702101A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
CN101883760A (zh) * 2007-10-11 2010-11-10 沃泰克斯药物股份有限公司 用作电压-门控钠通道抑制剂的杂芳基酰胺类
US8153651B2 (en) * 2007-11-13 2012-04-10 Evotec Ag Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US8188280B2 (en) * 2008-02-06 2012-05-29 Msd K.K. 3-substituted sulfonyl piperidine derivative
JP2011522524A (ja) * 2008-05-13 2011-08-04 ケイマン ケミカル カンパニー 化合物又は製剤における造血プロスタグランジンdシンターゼの有力リガンドを置換する能力をアッセイする方法
TW201010997A (en) 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
CA2725481A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
KR101252335B1 (ko) 2009-07-16 2013-04-08 (주)아모레퍼시픽 피부 노화 방지용 조성물
WO2010056044A2 (ko) * 2008-11-11 2010-05-20 (주)아모레퍼시픽 바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물
KR101367057B1 (ko) 2009-03-17 2014-02-25 (주)아모레퍼시픽 피부 자극 완화용 조성물
RU2496778C2 (ru) 2009-03-09 2013-10-27 Тайхо Фармасьютикал Ко., Лтд. Пиперазиновое соединение, ингибирующее простагландин-d-синтазу
CN107875155A (zh) * 2009-10-08 2018-04-06 赛诺菲 苯基噁二唑衍生物在制备治疗变应性或炎性疾病的药物中的用途
EP2527340B1 (en) 2010-01-22 2016-08-17 Taiho Pharmaceutical Co., Ltd. Piperazine compound having a pgds inhibitory effect
US9320723B2 (en) * 2010-05-03 2016-04-26 University Of Rochester Methods of treating thyroid eye disease
US9199976B2 (en) 2010-06-01 2015-12-01 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
TW201217335A (en) 2010-09-07 2012-05-01 Taiho Pharmaceutical Co Ltd Prostaglandin d synthase inhibitory piperidine compounds
KR101271223B1 (ko) 2011-01-27 2013-06-07 한국과학기술연구원 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제
CA2860672A1 (en) 2012-01-06 2013-07-11 University Of South Florida Compositions, methods of use, and methods of treatment
CN108430992A (zh) 2015-12-17 2018-08-21 阿斯特克斯医疗公司 作为h-pgds抑制剂的喹啉-3-甲酰胺
WO2017160832A1 (en) * 2016-03-14 2017-09-21 Emory University Amide-sulfamide derivatives, compositions, and uses related to cxcr4 inhibition
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
EP3638672A1 (en) 2017-06-13 2020-04-22 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds as h-pgds inhibitors
TWI695000B (zh) * 2017-10-29 2020-06-01 中國醫藥大學 用於抑制adam9活性之化合物、其醫藥組合物及其用途
CA3085293A1 (en) 2017-12-13 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Fused pyridines which act as inhibitors of h-pgds
WO2019179652A1 (en) * 2018-03-23 2019-09-26 Step Pharma S.A.S. Aminopyrimidine derivatives as ctps1 inhibitors
JP2022506850A (ja) 2018-11-08 2022-01-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 化学化合物
CA3182912A1 (en) * 2020-05-13 2021-11-18 Chdi Foundation, Inc. Htt modulators for treating huntington's disease
WO2021256569A1 (ja) 2020-06-19 2021-12-23 佐藤製薬株式会社 H-pgdsを阻害する縮環化合物
US12331046B2 (en) * 2020-10-23 2025-06-17 Nimbus Clotho, Inc. CTPS1 inhibitors and uses thereof
CN113004208A (zh) * 2021-03-08 2021-06-22 沈阳药科大学 一种抑制黄嘌呤氧化酶活性的化合物及制备方法和应用
MX2024005933A (es) * 2021-11-17 2024-08-06 Chdi Foundation Inc Moduladores de htt pata tratar la enfermedad de huntington.
CA3240926A1 (en) * 2021-12-17 2023-06-22 Sato Pharmaceutical Co., Ltd. Azaindole derivative inhibiting h-pgds
KR20240154607A (ko) * 2022-02-28 2024-10-25 니뽄 다바코 산교 가부시키가이샤 인다졸 화합물 및 그 의약 용도

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU997598A3 (ru) * 1979-08-27 1983-02-15 Басф Аг (Фирма) Гербицидное средство
JP2000226372A (ja) * 1999-02-01 2000-08-15 Nippon Soda Co Ltd アミド化合物、その製造方法及び農園芸用殺虫剤
WO2001070671A2 (en) * 2000-03-22 2001-09-27 E.I. Du Pont De Nemours And Company Insecticidal anthranilamides
WO2004072069A1 (en) * 2003-02-14 2004-08-26 Glaxo Group Limited Carboxamide derivatives
EP1471057A1 (en) * 2003-04-25 2004-10-27 Bayer HealthCare AG Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2
WO2005032493A2 (en) * 2003-10-07 2005-04-14 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd N―(1h―テトラゾール―5―イル)―2―フェニル―5―ピリミジンカルボキシアミド類及びその合成用中間体
GB9405347D0 (en) * 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
JP2002003370A (ja) * 1999-09-20 2002-01-09 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
EP1218336A2 (en) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
JP2003112985A (ja) 2001-10-01 2003-04-18 Nre Happiness Kk 食品残渣肥、飼料原料化システムおよびそれに使用する破砕貯留処理ユニット並びに乾燥冷却処理ユニット
JPWO2004011430A1 (ja) * 2002-07-25 2005-11-24 アステラス製薬株式会社 ナトリウムチャネル阻害剤
CA2494102A1 (en) * 2002-07-30 2004-02-05 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
EP1737414A2 (en) * 2004-01-23 2007-01-03 Amgen Inc. Vanilloid receptor ligands and their use in treatments of inflammatory and neuropatic pain
PE20110118A1 (es) 2005-10-04 2011-03-08 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU997598A3 (ru) * 1979-08-27 1983-02-15 Басф Аг (Фирма) Гербицидное средство
JP2000226372A (ja) * 1999-02-01 2000-08-15 Nippon Soda Co Ltd アミド化合物、その製造方法及び農園芸用殺虫剤
WO2001070671A2 (en) * 2000-03-22 2001-09-27 E.I. Du Pont De Nemours And Company Insecticidal anthranilamides
WO2004072069A1 (en) * 2003-02-14 2004-08-26 Glaxo Group Limited Carboxamide derivatives
EP1471057A1 (en) * 2003-04-25 2004-10-27 Bayer HealthCare AG Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2
WO2005032493A2 (en) * 2003-10-07 2005-04-14 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PALANKI М S S ET AL: "INHIBITORS OF NF-KAPPABETA AND AP-1 GENE EXPRESSION: SAR STUDIES ON THE PYRIMIDINE PORTION OF 2-CHLORO-4-TRIFLUOROMETHYLPYRIMIDINE-5-N-(3′,5′-BIS(TRIFLUOROMETHYL)-PHENIL)CARBOXAMIDEL", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETE, 2000, p.3995-4004, ex.94. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2655914C2 (ru) * 2012-08-24 2018-05-30 Саншайн Лейк Фарма Ко., Лтд. Соединения дигидропиримидина и их применение в фармацевтических препаратах
RU2655914C9 (ru) * 2012-08-24 2018-07-24 Саншайн Лейк Фарма Ко., Лтд. Соединения дигидропиримидина и их применение в фармацевтических препаратах

Also Published As

Publication number Publication date
CR9832A (es) 2008-06-18
EP1937652A1 (en) 2008-07-02
AU2006299428B2 (en) 2012-04-26
TNSN08104A1 (en) 2009-07-14
JP2009510170A (ja) 2009-03-12
CA2624749C (en) 2011-08-16
AR056871A1 (es) 2007-10-31
TWI415839B (zh) 2013-11-21
CN101538246A (zh) 2009-09-23
NO20082000L (no) 2008-06-09
PE20070589A1 (es) 2007-06-22
ES2514471T3 (es) 2014-10-28
SG166121A1 (en) 2010-11-29
NZ567208A (en) 2011-03-31
MA29925B1 (fr) 2008-11-03
JP5452925B2 (ja) 2014-03-26
IL190411A0 (en) 2008-11-03
US8202863B2 (en) 2012-06-19
CN101282943A (zh) 2008-10-08
IL190411A (en) 2013-09-30
PE20110118A1 (es) 2011-03-08
AU2006299428A1 (en) 2007-04-12
WO2007041634A1 (en) 2007-04-12
BRPI0616815A2 (pt) 2011-07-05
US20080227782A1 (en) 2008-09-18
EP1937652B1 (en) 2014-07-30
DOP2006000210A (es) 2007-06-15
UY29840A1 (es) 2007-05-31
CN101538246B (zh) 2014-07-16
MY151172A (en) 2014-04-30
ZA200802222B (en) 2009-09-30
KR101457966B1 (ko) 2014-11-04
UA93213C2 (en) 2011-01-25
KR20080050611A (ko) 2008-06-09
TW200812977A (en) 2008-03-16
ECSP088335A (es) 2008-05-30
CA2624749A1 (en) 2007-04-12
RU2008117170A (ru) 2009-11-10

Similar Documents

Publication Publication Date Title
RU2420519C2 (ru) Пиримидинамидные соединения как ингибиторы pgds
RU2464262C2 (ru) Пиримидингидразидные соединения как ингибиторы pgds
RU2417990C2 (ru) 2,6-замещенные-4-монозамещенный амино-пиримидины как антагонисты рецептора простагландина d2
US9447090B2 (en) Imidazopyridine compounds
US8637510B2 (en) Morpholinothiazoles as alpha 7 positive allosteric modulators
US20070265278A1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
US8338614B2 (en) Tertiary carbinamines having substituted heterocycles which are active as β-secretase inhibitors for the treatment of alzheimer's disease
JP2007530694A (ja) ナトリウムチャネル遮断薬としてのビアリール置換ピラジノン
KR20070084035A (ko) 비방향환 축합 피리미딘 유도체
US7446112B2 (en) Modulators of muscarinic receptors
AU2008244576A1 (en) 2-substituted indole derivatives as calcium channel blockers
JP4875610B2 (ja) 置換5,6,7,8−テトラヒドロ−ピリド[4,3−d]ピリミジン−2−イル化合物および5,6,7,8−テトラヒドロ−キナゾリン−2−イル化合物
AU2006304187A1 (en) Dihydrogen phosphate salt of a prostaglandin D2 receptor antagonist
HK1136162A (en) Pyrimidine amide compounds as pgds inhibitors
US20090176836A1 (en) Cyclic Ketal Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
JP2012504128A (ja) カルシウムチャネル遮断薬としての置換アリールスルホン誘導体

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20151005